uniQure Announces Positive Results for Huntington’s Study

uniQure ( (QURE) ) has shared an update.

On September 24, 2025, uniQure announced positive topline results from its pivotal Phase I/II study of AMT-130 for Huntington’s disease, demonstrating a statistically significant 75% slowing of disease progression at 36 months in high-dose patients, compared to a control group. The study met its primary endpoint and showed favorable trends in secondary endpoints, with AMT-130 being well-tolerated and no new serious adverse events reported since December 2022. The company plans to discuss these results with the FDA, aiming for a Biologic License Application submission in early 2026, potentially impacting the treatment landscape for Huntington’s disease.

The most recent analyst rating on (QURE) stock is a Buy with a $76.00 price target. To see the full list of analyst forecasts on uniQure stock, see the QURE Stock Forecast page.

Spark’s Take on QURE Stock

According to Spark, TipRanks’ AI Analyst, QURE is a Neutral.

uniQure’s overall stock score reflects significant financial challenges, with declining revenues and a weak balance sheet being major concerns. Despite these issues, the stock shows positive technical momentum, and the company has made notable clinical advancements, particularly with AMT-130. However, the negative P/E ratio and lack of dividend yield limit its valuation appeal.

To see Spark’s full report on QURE stock, click here.

More about uniQure

uniQure N.V. is a leading gene therapy company focused on developing transformative therapies for patients with severe medical needs. The company is advancing its gene therapy candidate, AMT-130, for the treatment of Huntington’s disease, a neurodegenerative disorder.

Average Trading Volume: 2,247,225

Technical Sentiment Signal: Buy

Current Market Cap: $2.61B

For a thorough assessment of QURE stock, go to TipRanks’ Stock Analysis page.